Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P09619
UPID:
PGFRB_HUMAN
Alternative names:
Beta platelet-derived growth factor receptor; Beta-type platelet-derived growth factor receptor; CD140 antigen-like family member B; Platelet-derived growth factor receptor 1
Alternative UPACC:
P09619; B5A957; Q8N5L4
Background:
Platelet-derived growth factor receptor beta (PDGFRB) plays a pivotal role in embryonic development, cell proliferation, differentiation, and migration. It is crucial for blood vessel development and the recruitment of pericytes and smooth muscle cells, facilitating the formation of a branched network of capillaries in various organs.
Therapeutic significance:
PDGFRB's involvement in diseases such as Myeloproliferative disorder chronic with eosinophilia, Acute myelogenous leukemia, and others, highlights its potential as a target for therapeutic intervention. Understanding PDGFRB's role could pave the way for novel treatments for these malignancies.